Efficacy and safety of transarterial chemoembolization combined with camrelizumab and apatinib in treatment of advanced hepatocellular carcinoma
10.3969/j.issn.1001-5256.2022.12.014
- VernacularTitle:经肝动脉化疗栓塞术联合卡瑞利珠单抗及阿帕替尼治疗中晚期肝细胞癌的效果及安全性分析
- Author:
Yihan YANG
1
;
Wanci LI
1
;
Binyan ZHONG
1
;
Jian SHEN
1
;
Xiaoli ZHU
1
Author Information
1. Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, China
- Publication Type:Original Articles_Liver Neoplasms
- Keywords:
Carcinoma, Hepatocellular;
Camrelizumab;
Apatinib
- From:
Journal of Clinical Hepatology
2022;38(12):2755-2760
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of transarterial chemoembolization (TACE) combined with camrelizumab and apatinib in the treatment of advanced hepatocellular carcinoma (HCC). Methods From July 2019 to June 2021, 19 patients with advanced HCC who met the inclusion and exclusion criteria in the First Affiliated Hospital of Soochow University were enrolled in this study. All patients received TACE combined with camrelizumab and apatinib. Tumor response was assessed according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST), and adverse events were assessed according to Common Terminology Criteria for Adverse Events (v5.0). The Kaplan-Meier method was used to analyze progression-free survival and overall survival and calculate 95% confidence interval (CI). Results The median follow-up time was 14.0 months for the 19 patients. As of the last follow-up based on mRECIST, 7 patients (7/19, 36.8%) achieved complete response, 9 (9/19, 47.4%) achieved partial response, and 2 (2/19, 10.5%) achieved stable disease. During follow-up, overall objective response rate and overall disease control rate reached 84.2% and 94.7%, respectively; the median duration of response reached 8.0 (3.4-13.0) months, and median progression-free survival reached 9.5 (95% CI : 4.7-14.3) months; the 6-month survival rate reached 100%, and the 12-month survival rate reached 78.9%. Among the 19 patients, 7 (36.8%) experienced serious adverse events. The most common adverse events of all grades included post-embolization syndrome after TACE (17/19, 89.5%), liver injury (14/19, 73.7%), hematologic toxicity (8/19, 42.1%), and proteinuria (8/19, 42.1%). Conclusion TACE combined with camrelizumab and apatinib has marked efficacy and controllable adverse events in the treatment of advanced HCC, which provides a potential new option for the first-line treatment of advanced HCC.
